| Old Articles: <Older 7661-7670 Newer> |
|---|
 |
The Motley Fool
July 19, 2011
Brian Orelli |
J&J: Better, but Not Best A decent-looking quarter, but a turnaround could still take awhile.   |
The Motley Fool
July 19, 2011 |
IDEXX Laboratories Earnings Preview Investors are on the edge of their collective seats, hoping that IDEXX Laboratories will top analyst expectations for the fifth consecutive quarter on Friday, July 22. |
The Motley Fool
July 19, 2011
Brian Orelli |
Free Cash, But Be Careful Nabi trades below today's cash, but maybe not next years. |
The Motley Fool
July 18, 2011
Brian Orelli |
A $3.6 Billion Franchise at Stake Amgen and Teva settle their patent dispute, and Amgen investors have a little better idea of when the company's $3.6 billion Neupogen and Neulasta franchise might come under attack in the United States. |
The Motley Fool
July 18, 2011
Travis Hoium |
Pharmaceutical Product Development Shares Popped: What You Need to Know Shares of research group Pharmaceutical Product Development jumped as much as 18% this morning on potential merger talks. |
The Motley Fool
July 18, 2011
Seth Jayson |
Here's Why Qiagen NV's Latest Report Might Worry You What's going on with the inventory at Qiagen NV? The storeroom looks a little packed. |
The Motley Fool
July 16, 2011 |
VCA Antech Earnings Preview VCA Antech will unveil its latest earnings on Monday, July 18. |
The Motley Fool
July 16, 2011 |
Medtronic Invests in California Eye Lens Implant Company The new device aims to mimic a natural lens. |
The Motley Fool
July 16, 2011
Melly Alazraki |
HIV Studies May Not Mean Much to Gilead Studies find Gilead drugs can help prevent HIV infections, but that may not help sales. |
The Motley Fool
July 16, 2011 |
Exponent Earnings Preview Exponent will unveil its latest earnings on Wednesday, July 20. |
| <Older 7661-7670 Newer> Return to current articles. |
